Muscle loss may signal higher nerve risk during breast cancer treatment

NCT ID NCT06996548

First seen Jan 08, 2026 · Last updated Apr 29, 2026 · Updated 17 times

Summary

This completed study looked at 120 women with early-stage breast cancer to see if having low muscle mass (sarcopenia) before treatment makes them more likely to develop nerve damage from the chemotherapy drug paclitaxel. Researchers measured muscle mass on CT scans and checked for nerve symptoms using questionnaires and nerve tests. The goal is to help doctors identify high-risk patients early and possibly adjust treatment to prevent long-term nerve problems.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Ankara Etlik City Hospital

    Ankara, Yenimahalle, 06170, Turkey (Türkiye)

  • Dr. Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital

    Ankara, Yenimahalle, 06200, Turkey (Türkiye)

  • Gazi University

    Ankara, Yenimahalle, 06560, Turkey (Türkiye)

Conditions

Explore the condition pages connected to this study.